Search Results for

Showing 1 - 10 of 18 results
  1. Trending topics: Patient engagement

    Trending topics Patients: From consumers to partners Passenger. End user. Spectator. These are terms that many in biomedical research would use to describe the role patients play as a potential therapy winds its way along the development pipeline. Yet, a growing number of patients are no longer content to simply watch and wait as possible life-changing science happens without them.  “Other than providing funding, the patient community hasn’t traditionally been given the opportunity to intera

  2. NEI director's message

    NEI director’s message Updates, challenges, progress and the 50-year celebration Paul A. Sieving, MD, PhD, FARVO  NEI launched the Eyes of Infants with Zika (EIZ) study in June with the help of Brazilian investigators. As you may recall, in summer 2015 epidemiologists observed that Zika virus infection during pregnancy could result in babies with severe microcephaly. In response to this alarming news, NIH mounted a multi-Institute effort to follow a Zika-exposed cohort of pregnant women to s

  3. Journals column

    ARVO Journals Editors-in-chief prepare for new term In May 2016, ARVO members elected editors-in-chief (EICs) for the association’s three journals. The new EICs will officially begin their five-year terms in January 2018. Each recently shared parts of their vision for their respective journals with ARVONews. Donald Hood, PhD, FARVO Columbia University ARVONews: All new editors want to improve their journal. How are you going to go about this? In the statement I submitted when running for edi

  4. Leaders-Volunteers: New Trustees

    Leaders and volunteers Conversations with the new Trustees T. Michael Redmond, PhD, FARVO Biochemistry/Molecular Biology Section National Eye Institute/NIH What do you look forward to the most about being a member of the ARVO Board of Trustees? I hope to serve by advancing the mission of ARVO and furthering its impact on biomedical research and health in these critical times for both science and health. I think that ARVO must be in the vanguard of supporting continued investment in research

  5. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

  6. Spotlight on members: 5 members in 5

    Spotlight on members Five members in five minutes Boost your research with social media advice from ARVO members  Laura Downie, BOptom, PhD, FAAO Lecturer and NHMRC TRIP Fellow Department of Optometry & Vision Science, University of Melbourne @DrLauraDownie “Social media has emerged as a valuable tool for researchers to disseminate their research, build their collaborative networks and demonstrate research impact beyond the academic sphere. In my experience, Twitter has been an effect

  7. Around the globe: IT-ARVO

    Around the globe International Chapter Affiliate news IT-ARVO acts on animals in research regulations This is part of a series of articles that highlight members and activities of ARVO’s 13 International Chapter Affiliates (ICAs). The Italy Association for Research in Vision and Ophthalmology (IT-ARVO) officer Fillipo Drago, MD, PhD, FARVO, weighs in on the increased restrictions on the use of animals in research and how the research community in Italy has responded to these tighter regulati

  8. ARVO Foundation: Epstein awardee

    ARVO Foundation Linking mentor, mentee and good science Dr. David L. Epstein Award honors recipients Jonathan Crowston and Peter van Wijngaarden Jonathan Crowston, MBBS, PhD, and Peter van Wijngaarden, MBBS, PhD, speak with the easy-going rapport of two people who have worked together for years. And they have. Crowston and his mentee, van Wijngaarden, collaborate closely at the Centre for Eye Research Australia in Melbourne. They are the first recipients of the Dr. David L. Epstein Award, a $

  9. Chair's letter

    ARVO Foundation Message from the chair J. Mark Petrash, PhD, FARVO Research without borders One of the goals of the ARVO Foundation for Eye Research is to support the education and training of vision scientists worldwide. The Developing Country Eye Research Travel Fellowship program (DCERF), administered by the ARVO Foundation, supports trainees from underserved countries to participate in the ARVO Annual Meeting. In the program’s 10-year history, 114 trainees from 44 countries have made the

  10. Spotlight on members: Beckman-Argyros awardee

    Spotlight on members Extending OCT from structure to function  Beckman-Argyros Award furthers research of James Fujimoto Scientists are all too aware of the gap between high risk, high impact ideas and the funding necessary to pursue them. Fortunately, so is the Arnold and Mabel Beckman Foundation. Through its Beckman-Argyros Award in Vision Research, the Foundation funds potentially high-impact work that lacks the full suite of data necessary to secure government funding. Through this year’s